Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Price Down 4.9% – What’s Next?

Zealand Pharma A/S (OTCMKTS:ZLDPF)’s share price traded down 4.9% during trading on Thursday . The stock traded as low as $49.2850 and last traded at $49.2850. 330 shares traded hands during mid-day trading, a decline of 88% from the average daily volume of 2,757 shares. The stock had previously closed at $51.8050.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Berenberg Bank lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, June 17th. Jefferies Financial Group downgraded Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Wells Fargo & Company reiterated an “overweight” rating on shares of Zealand Pharma A/S in a research note on Thursday, August 13th. Finally, Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold”.

Zealand Pharma A/S Price Performance

The business’s 50-day moving average price is $46.72 and its 200 day moving average price is $48.40. The company has a market capitalization of $3.53 billion, a P/E ratio of 8.17 and a beta of 0.88. The company has a quick ratio of 37.17, a current ratio of 37.17 and a debt-to-equity ratio of 0.02.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.